Member access

4-Traders Homepage  >  Shares  >  Euronext Paris  >  SANOFI    SAN   FR0000120578


SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll news 

Sanofi: Tests Show Zaltrap Improves Colorectal Cancer Survival Rate

10/08/2012 | 01:44am US/Eastern

French drug company Sanofi SA (>> SANOFI) Monday said results from the pivotal Phase III Velour study evaluating Zaltrap showed improvement in overall survival rate to colorectal cancer.


- Sanofi said the Journal of Clinical Oncology published the results of the study evaluating Zaltrap effects.

- In the Velour trial evaluating metastatic colorectal cancer patients previously treated with an oxaliplatin-containing regimen, Zaltrap in combination with the Folfiri chemotherapy regimen (5-fluorouracil, leucovorin, irinotecan) showed a statistically significant improvement in overall survival, progression-free survival, and the overall tumor response rate versus placebo plus Folfiri.

- The Velour data supported the regulatory approval of Zaltrap by the U.S. Food and Drug Administration (FDA) on August 3, 2012 after a Priority Review.

- Zaltrap is under review at the European Medicines Agency and other regulatory agencies worldwide, Sanofi says.

-Write to Inti Landauro at

Subscribe to WSJ:

Stocks mentioned in the article : SANOFI
React to this article
Latest news on SANOFI
2d ago SANOFI : and Regeneron's atopic dermatitis drug receives FDA breakthrough therap..
2d ago SANOFI : Outlines Next Wave of Innovative Medicines and Vaccines
2d ago SANOFI : Launches shan5 vaccine
2d ago SANOFI : : European CHMP Adopts Positive Opinion for Genzyme's Cerdelga® (eliglu..
2d ago SANOFI : European CHMP Adopts Positive Opinion for Genzyme’s Cerdelga® (el..
3d agoDJADR Shares End Mixed; Sanofi Shares Trade Actively
3d ago Sanofi touts new drugs but diabetes outlook disappoints
3d agoDJSANOFI : Sees $38 Billion New Drugs Sales Boost
3d agoDJSANOFI : Expects $38 billion Sales Boost from New Drugs
3d ago SANOFI : and Regeneron Announce that Dupilumab Has Received FDA Breakthrough The..
Duration : Period :
SANOFI Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes